REINFORCER Monitoring Plan

Protocol name:	tREatment of triangular FibrOcaRtilage ComplEx Ruptures (REINFORCER): Protocol for trial comparing debridement versus diagnostic arthroscopy in central tears and physiotherapy versus repair in ulnar tears
Version No.:	English version 1.0 for monitoring in Denmark and Sweden
Sponsor:	Pirkanmaa Hospital District
ClinicalTrials.gov	NCT04576169
Study Period:	02/2020-
Coordinating Investigator:	Ville Mattila
Study Sites:	Copenhagen University Hospital Gentofte, Denmark Hospital of Southern Jutland, Soenderborg, Denmark Södersjukhuset Stockholm, Sweden
Clinical Monitoring Monitor / Sites:	Monitor, Denmark Copenhagen University Hospital Gentofte, Denmark Hospital of Southern Jutland, Soenderborg, Denmark Monitor, Sweden Södersjukhuset Stockholm, Sweden

DESCRIPTION OF THE MONITORING ACTIVITIES

Study Protocol:

tREatment of triangular FibrOcaRtilage ComplEx Ruptures (REINFORCER): Protocol for trial comparing debridement versus diagnostic arthroscopy in central tears and physiotherapy versus repair in ulnar tears

Kolmiorustorepeämien hoito (REINFORCER): Tutkimussuunnitelma vertailevalle tutkimukselle puhdistusleikkauksen ja lumekirurgian välillä keskiosan ja värttinäluun puoleisten repeämien sekä fysioterapian ja korjauksen kyynärluun puoleisissa repeämissä

This document is a description of the planned monitoring activities for the above-mentioned study. This Monitoring Plan is valid until further notice, and it can be updated by mutual agreement.

The required monitoring services for this study will be provided by Danish study monitor for Coepenhagen and Soenderborg, and Swedish study monitor for Stockholm.

Kaivorinne A, *et al. BMJ Open* 2024; 14:e086102. doi: 10.1136/bmjopen-2024-086102

REINFORCER Monitoring Plan

Pirkanmaa Hospital District

The General Rules for Interpreting this Monitoring plan

The Protocol shall prevail over this Monitoring plan. The Protocol should be applied also in situations where something is not agreed in this Monitoring plan. After that in the event of any inconsistency between any of guidelines, laws, regulations, practices, or directions prescribing the higher standard or practice will apply.

1. Monitoring Services

The purposes of trial monitoring are to verify that the rights and well-being of human subjects participating in the study are protected, the reported trial data are accurate, complete, and verifiable from source documents. The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirement(s).

Principal Investigator of each study site shall permit the Study Monitor access to all relevant clinical data of the Clinical Study Subjects for monitoring and source data verification, such access to be arranged at mutually convenient times and on reasonable notice.

1.1 Site Initiation Visit

Not applicable

1.2 Monitoring Visit

During the study, the monitoring visit will be performed as follows

The monitoring visit schedule:

2023-2024 sites in Coepenhagen, Soenderborg, and Stockholm

Monitoring visits after 2024 will be agreed separately

This plan will be updated during the study if necessary. Additional visits, contacts or a review of additional patients' data may be performed if serious issues are detected.

The Coordinating Investigator should be notified by the monitor promptly after the observation of critical/urgent findings. In case of open findings, the issues affecting patient safety and/or data

integrity will be checked during the next monitoring visit at the study site or at an off-site contact in between monitoring visits.

The on-site monitoring visit will include, but is not limited, the following activities:

- ✓ Review of the Investigator's Site File
- ✓ Review of the facilities and resources at the site
- ✓ Review of the compliance to study protocol and study specific procedures
- ✓ Review of source document quality
- ✓ Review of the completeness of the eCRF documentation
- ✓ Review of the completeness, accuracy and filing of the drug accountability records

A complete review (100 % SDV) will be conducted for a random sample of 10% of the trial subjects (randomized).

All the subjects will be monitored for:

- ✓ Informed consent process
- ✓ SAE/SUSAR reporting
- ✓ Withdrawal or discontinuation

Following key items will be monitored in 20% (random sample of patients) of the study subjects (which are not monitored in 100%):

- ✓ Eligibility (Inclusion / exclusion criteria)
- ✓ Correct randomization (subjects receive treatment in accordance with randomization and protocol)
- ✓ Adverse event (AE) -reporting
- ✓ Documentation of the 2 years follow-up assessments
- ✓ Documentation of the 5 years follow-up assessments
- ✓ Documentation of the 10 years follow-up assessments

1.3 Close-out Visit

After the last study subject has performed the last visit a monitoring visit combined with the closeout monitoring visit should take place at each site.

1.4 Agreement and conduction of the monitoring visit

The monitor agrees on an appointment with site by an email to the Local Principal Investigator and in "cc" to the applicable study team members and the Coordinating Investigator.

1.5 Visit reporting

- ✓ The Study Monitor will report all significant findings, deviations, deficiencies, activities, discussions and conclusions of the visit in a Monitoring Visit Report within 2 weeks of the monitoring visit.
- ✓ The Monitoring Visit Report will be sent to the Sponsor / Coordinating Investigator for approval and signature.
- ✓ The original signed report will be filed in the Trial Master File (TMF) and copy of monitoring report in ISF.
- ✓ A follow-up letter summarizing the findings discovered during the visit will be sent to the local PI and the Study coordinator/Study nurse.
- ✓ Additionally, the follow-up letter will be sent in "cc" to the Coordinating Investigator
- ✓ Principal Investigator will be responsible for arranging the needed corrective actions at the site after the monitoring visit (within 4 weeks).

The visit report should at least contain the following information:

- ✓ Visit date, site name, and trial name
- ✓ Names and function of site staff present during the visit
- ✓ Activities performed and documents reviewed during the visit
- ✓ Findings from the visit and a summary of the discussion of findings
- ✓ Corrective actions resulting from the visit

2. Guidelines to be followed

This monitoring agreement is made in collaboration with the guideline for coordinated GCPmonitoring of clinical trials in the Nordic countries (version 5/24.10.2017), the Study Protocol and has been written in cooperation with the Sponsor / the Principal Investigator.
The Study Monitor will conduct the monitoring visits in accordance with ICH-GCP, regulatory requirements, study protocol and amendments (if any), SOP "Monitoring Services Provided by the University Hospital Research Units" and this Agreement.
The monitoring plan will be evaluated on ongoing basis, after every approved amendment and according to Sponsor's, Principal Investigator's, and The Study Monitor's evaluation.

The findings of the monitoring visits shall be grated according to the Europe commission's GUIDANCE FOR THE PREPARATION OF GOOD CLINICAL PRACTICE INSPECTION REPORTS (Version: 28 May 2008), in practical terms: Critical-Major-Minor-Comments.

3. Commencement

This monitoring plan is valid after sponsor's written confirmation.

REINFORCER Monitoring Plan

Pirkanmaa Hospital District

4. Signatures:

The following monitoring plan is approved by both parties and will apply until up-dates are mutually agreed.

_____	_____
Date and place	Ville Mattila Sponsor / Coordinating Investigator
_____	_____
Date and place	Study Monitor

Kaivorinne A, *et al*. *BMJ Open* 2024; 14:e086102. doi: 10.1136/bmjopen-2024-086102